Metastatic adult Wilms' tumor managed by chemotherapy, immunotherapy and target therapy: a case report

References

• Segers H, van den Heuvel-Eibrink MM, Pritchard-Jones K et al. Management of adults with Wilms'tumor: recommendations based on international consensus. Exp. Rev. Anticancer Ther. 2011(11), 1105–1113 (2011).
   Google Scholar
• Kattan J, Tournade MF, Culine S et al. Adult Wilms' tumour: review of 22 cases. Eur. J. Cancer 30A, 1778–1782 (1994).
   PubMed Web of Science ®Google Scholar
• Terenziani M, Spreafico F, Collini P et al. Adult Wilms' tumor: a monoinstitutional experience and a review of the literature. Cancer 101(2), 289–293 (2004).
   PubMed Web of Science ®Google Scholar
• Reinhard H, Aliani S, Ruebe C et al. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93–01/Society for Pediatric Oncology and Hematology (GPOH) study. J. Clin. Oncol. 22(22), 4500–4506 (2004).
   PubMed Web of Science ®Google Scholar
• Kalapurakal JA, Nan B, Norkool P et al. Treatment outcomes in adults with favorable histologic type Wilms' tumor-an update from the National Wilms' Tumor Study Group. Int. J. Radiat. Oncol. Biol. Phys. 60(5), 1379–1384 (2004).
   PubMed Web of Science ®Google Scholar
• Mitry E, Ciccolallo L, Coleman MP et al. Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study. Eur. J. Cancer 42(14), 2363–2368 (2006).
   PubMed Web of Science ®Google Scholar
• Vishnupriya S, Ismail ZA, Devashree V. Recent Improvements in Adult Wilms Tumor Diagnosis and Management: Review of Literature. J. Kidney Cancer VHL. 10(3), 32–36 (2023).
   PubMed Web of Science ®Google Scholar
• Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr. Pathol. 10, 1–36 (1990).
   PubMedGoogle Scholar
• Re GG, Hazen-Martin DJ, Sens DA et al. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development. Semin. Diagn. Pathol. 11(2), 126–135 (1994).
   PubMed Web of Science ®Google Scholar
• Maschietto M, Richard D, Tasnim C et al. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLOS ONE 9(10), e109924 (2014).
   PubMed Web of Science ®Google Scholar
• Saltzman AF, Carrasco A Jr, Amini A et al. Patterns of Care and Survival Comparison of Adult and Pediatric Wilms Tumor in the United States: A Study of the National Cancer Database. Urology 9(10), e109924 (2020).
   Google Scholar
• Toumade MF, Corn-Nouge C, Voute P et al. Results of the Sixth International Society of Pediatric Oncology Wihns' Tumor Trial and Study: a risk adapted therapeutic approach in Wihns' tumor. J. Clin. Oncol. 1993 11, 1014–1023 (1993).
   Google Scholar
• Huszno J, Starzyczny-Słota D, Jaworska M et al. Adult Wilms' tumor – diagnosis and current therapy. Cent. European J. Urol. 66(1), 39–44 (2013).
   PubMedGoogle Scholar
• Green DM. The treatment of stages I–IV favorable histology Wilms' tumor. J. Clin. Oncol. 22, 1366–1372 (2004).
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH et al. Response rates in relapsed Wilms' tumor. A need for new effective agents. Cancer 67(3), 567–571 (1991).
   PubMed Web of Science ®Google Scholar
• Mancheril BG, Waddell JA, Solimando DA Jr et al. Nab-Paclitaxel and Carboplatin (Nab-PC) Regimen for Advanced Non-Small-Cell Lung Cancer. Hosp. Pharm. 49(9), 804–808 (2014).
   PubMedGoogle Scholar
• Miyako S, Isamu O, Hiroshi S et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 81(1), 97–101 (2013).
   PubMed Web of Science ®Google Scholar
• Untch M, Jackisch C, Schneeweiss A et al. Nab‐paclitaxel versus solvent‐based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto‐GBG 69): a randomised, phase 3 trial. Lancet Oncol. 17, 345–356 (2016).
   PubMed Web of Science ®Google Scholar
• Yuan Y, Lee JS, Yost SE et al. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. Oncologist 26(3), e382–e393 (2021).
   PubMed Web of Science ®Google Scholar
• Yardley DA, Coleman R, Conte P et al. Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann. Oncol. 29(8), 1763–1770 (2018).
   PubMed Web of Science ®Google Scholar
• Yang W, Xing X, Yeung SJ et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J. Immunother. Cancer 10(1), e003497 (2022).
   PubMed Web of Science ®Google Scholar
• Wang L, Li S, Zhu D, Qin Y et al. Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study. J. Gynecol. Oncol. 34(4), e44, (2023).
   PubMed Web of Science ®Google Scholar
• Hirsh V, Okamoto I, Hon JK et al. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J. Thorac. Oncol. 9(1), 83–90 (2014).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794–803 (2005).
   PubMed Web of Science ®Google Scholar
• Holl EK, Routh JC, Johnston AW et al. Immune expression in children with Wilms tumor: a pilot study. J. Pediatr. Urol. 15(5), 441.e1–441.e8 (2019).
   PubMed Web of Science ®Google Scholar
• Routh JC, Grundy PE, Anderson JR et al. B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor. J. Urol. 189(4), 1487–1492 (2013).
   PubMed Web of Science ®Google Scholar
• Voron T, Marcheteau E, Pernot S et al. Control of the immune response by pro-angiogenic factors. Front Oncol. 4, 70 (2014).
   PubMedGoogle Scholar
• Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Urology 135, 50–56 (2020).
   PubMedGoogle Scholar
• Kumar S, Burney IA, Al-Moundhri MS. Near complete resolution of refractory, relapsed, metastatic Wilms' tumour in an adolescent with bevacizumab. J. Coll. Physicians Surg. Pak. 24(Suppl. 1), S71–S72 (2014).
   PubMedGoogle Scholar